RecruitingNot ApplicableNCT07243184

The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.

A Prospective, Multicenter Clinical Trial Evaluating the Feasibility and Safety of Polymer Artificial Heart Valve for the Treatment of Mitral Valve Diseases

Sponsor

Shanghai HeartEpoch Medical Technology Co., Ltd

Enrollment

10 participants

Start Date

Nov 19, 2025

Study Type

INTERVENTIONAL

Conditions

Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis

Summary

The study aims to evaluate the feasibility and safety of polymer artificial heart valve designed and developed by Shanghai HeartEpoch Medical technology Co. Ltd. for the treatment of the mitral valve diseases.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called mitral valve replacement for people with severe mitral valve regurgitation, severe mitral valve stenosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEmitral valve replacement

device: polymer artificial heart valve mitral valve replacement

Locations(1)

Beijing Anzhen Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07243184